Related Experiment Video

Updated: Aug 19, 2025

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.3K

Everolimus for Estrogen Receptor-negative Breast Cancer Prevention: A Journey Begun?

Lauren Nye1, Seema A Khan2

  • 1Breast Cancer Prevention and Survivorship Research Center, The University of Kansas Health System, Kansas City, Kansas.

Cancer Prevention Research (Philadelphia, Pa.)
|December 1, 2022
PubMed

Insights

Tamoxifen and other breast cancer prevention drugs show limitations. New research explores targeting the PI3K/AKT/mTOR pathway, but safety concerns remain for these novel therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Prevention

Background:

  • Tamoxifen, approved in 1998, is a prototypic medication for breast cancer prevention.
  • Subsequent drugs have demonstrated efficacy but face limitations: lack of protection against hormone receptor-negative breast cancer and poor safety/tolerability profiles.
  • These limitations affect a majority of women at increased risk for breast cancer.

Discussion:

  • Preclinical data suggest targeting the PI3K/AKT/mTOR signaling pathway may offer new avenues for breast cancer prevention.
  • Drugs like rapamycin and everolimus show provocative efficacy signals in preclinical studies.
  • However, the safety and tolerability profiles of these novel agents require careful consideration and further investigation.

Key Insights:

  • Current breast cancer prevention medications have significant limitations, particularly for hormone receptor-negative disease.
  • Targeting the PI3K/AKT/mTOR pathway presents a promising, yet unproven, strategy for future breast cancer prevention therapies.
  • The development of effective and well-tolerated breast cancer prevention strategies remains a critical unmet need.

Outlook:

  • Further research is essential to validate the efficacy of PI3K/AKT/mTOR inhibitors in breast cancer prevention.
  • Investigating the safety and tolerability of these agents is crucial before clinical application.
  • Developing novel therapeutic strategies that overcome existing limitations is key for advancing breast cancer prevention.

More Related Videos

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.2K
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

20.3K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
157
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K